Current Price{{movement}} ${{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{(quote['Price Qualifier Code'] == 'OPN' || quote['Price Qualifier Code'] == 'SUS') ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy
1 Day
Chart Type
Themes
Select Tool
Fill:
Line:
Axis Label:
  • Open:
  • High:
  • Close:
  • Low:
  • Volume:
  • Date:

Biotron Limited (BIT)
is a publicly listed company on the Australian Securities Exchange (ASX).


{{businessSummary}}

News

No News Available

{{item.Body}}



General Overview

About Biotron Limited

Biotron Limited (Biotron) is leading the way in the development of revolutionary new treatments for serious viral diseases such as HIV and Hepatitis C virus (HCV). Biotron has an impressive pipeline of clinical programs developing first-in-class antiviral drugs.

Biotron's lead drug, BIT225, is a viroporin inhibitor in clinical development for treatment of HCV and HIV, as well as the hard to treat HIV/HCV co-infected population. It has shown good anti-HCV activity in clinical trials to date, improving the outcome in patients with hard-to-treat genotype 1 HCV infection undergoing treatment with current approved therapy of interferon and ribavirin (100% receiving BIT225 (400mg) plus IFN/RBV were virus-free at 48 weeks, compared to 75% who received only IFN/RBV).

Preliminary results from the Phase 1b/2a HIV trial completed in late 2012 demonstrated that BIT225 targets HIV replication in monocyte cells in treated patients, significantly reducing virus levels in these cells. Patients enrolled in the study were HIV-infected, with high levels of virus and good CD4+ T cell counts. None had previously received treatment with anti-retroviral drugs. These results validate Biotron's novel approach to tackling HIV; targeting the virus reservoir, and positions BIT225 as having potential utility in future eradication strategies.

Due to BIT225's dual activity against HIV and HCV it is uniquely placed as a potential treatment in HIV/HCV co-infected patients. An interim analysis of 12 week data from the recently completed Phase 2 trial of BIT225 in HIV/HCV co-infected patients demonstrated that BIT225 enhanced anti-HCV activity of IFN/RBV in co-infected HIV-1/HCV genotype 3 patients.

Biotron has early-stage programs addressing other viral diseases including Dengue virus.

Company Overview

Biotron Limited (Biotron) is a publicly listed Australian biotechnology company based in Sydney, NSW. Biotron is committed to the development and commercialisation of novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1. Biotron has identified a new class of viral proteins as targets for potential intervention, and is developing novel small molecule therapeutics that target these proteins, specifically the p7 protein of HCV and Vpu protein of HIV.

Biotron's lead drug, BIT225, is in clinical development for treatment of both HIV and HCV, as well as the hard to treat HIV/HCV co-infected population. It offers potential as a new class of oral direct-acting antiviral drug for HCV that may be used in combination with either current treatment strategies or with new classes of direct-acting antiviral drugs in development.

BIT225 is also active against HIV. Preclinical and clinical efficacy data has indicated that BIT225 may represent a first-in-class opportunity to target the HIV virus in monocyte lineage cells where, until now, the virus has been able to 'hide' from current drug therapies. This pool of virus is long-lived and continually produces low level virus, even in patients on treatment with antiretroviral drugs.

In addition to its clinical stage programs for BIT225, Biotron has early stage programs target other viruses including Dengue. It also has a research and development program for next generation viroporin inhibitors for its HIV/HCV programs.

Hepatitis C Virus

Background

It is estimated that in the USA alone, some 4 million people have been infected with Hepatitis C with 2.7 million suffering from chronic infection. Worldwide, 180 million people are infected. Hepatitis C virus (HCV) causes inflammation of the liver, which may lead to fibrosis and cirrhosis, liver cancer and, ultimately, liver failure. Existing drugs for HCV have toxicity issues and limited effectiveness, with approximately 50% of infected people not responding to current therapies, leaving a significant need for new therapies that directly target and halt replication and production of the virus in patients.

P7 Inhibitor

Biotron's HCV program is focused on developing drugs to target the HCV p7 protein. HCV p7 is highly conserved and present in all 6 clades, with a critical role in virus assembly and release, and is a potential new target for therapeutic intervention. BIT225 is a novel small molecule viral assembly inhibitor that targets p7 and is in development for treatment of chronic HCV infection.

Preclinical Data
  • Identified as “hit” in HCV p7 bacterial assay
  • Inhibits p7 (HCV 1a) ion channel in planar lipid bilayers
  • Inhibits infectious clone JFH1 (HCV 2a)
  • Also inhibits HCV model viruses GBV-B & BVDV
  • Synergy with IFN, IFN/ribavirin, and polymerase inhibitors in BVDV in vitro
  • High barrier to antiviral resistance in vitro
  • Good preclinical safety and toxicology data
  • Phase 1b data showed antiviral efficacy against genotype 1-3
  • Viral assembly inhibitor with antiviral kinetics that suggest efficacy increases with treatment duration.
Clinical Data

A Phase 1a safety trial (BIT225-001) in healthy volunteers was completed in late 2007. A Phase 1b, repeat-dose monotherapy study (BIT225-003) in HCV-infected patients was completed in late 2009. The results demonstrated that BIT225 showed antiviral efficacy against genotype 1-3, significantly reducing viral loads compared to placebo, and that the drug was well tolerated. The antiviral kinetics suggested that efficacy increased with treatment duration.

The Phase 2a, 28-day, repeat-dose, combination trial (BIT225-005) of BIT225 with standard of care (pegylated interferon and ribavirin; IFN/RBV) in treatment-naive, genotype 1 HCV-infected patients was completed in August 2011. BIT225 demonstrated good anti-HCV activity, with treatment-naive, HCV genotype 1 patients receiving BIT225 in addition to IFN/RBV having significantly lower viral loads than those receiving IFN/RBV alone at the conclusion of dosing. The three-month complete EVR in patients who received BIT225 +IFN/RBV was 87%, compared to 63% in the IFN/RBV control group. The 48-week data extends the previous three-month data, demonstrating BIT225 continued to provide additional benefit to patients after the conclusion of dosing, with 100% SVR in patients who received BIT225 (400 mg) +IFN/RBV, compared to 75% in the IFN/RBV control group.

HCV/HIV Co-Infected

Due to BIT225's dual activity against HIV and HCV it is uniquely placed as a potential treatment in HIV/HCV co-infected patients. The proportion of patients infected with both HIV and HCV is significant, with 25 – 40% of HIV patients in the USA also infected with HCV. This co-infected group offers challenges to treatment with current therapies.

Biotron initiated a Phase 2 trial (BIT225-006) of BIT225 in combination with IFN/RBV in HIV/HCV co-infected patients in November 2012.

Advantages

BIT225 has the following advantages:

  • First-in-class, new mode of action drug
  • Novel p7 inhibitor with the potential to increase the potency of current anti-HCV therapy
  • Highly synergistic with ribavirin and rIFNa-2b
  • Potential for use in HCV and HIV-1 co-infected patients.

HIV

Background

Current antiretroviral therapy (ART) results in rapid suppression of viral load and improves the health and lifespan of the HIV infected individual. However, ART does not cure HIV infection and chronic therapy requires surveillance for drug side effects and drug-resistant virus. The majority of drugs approved or in clinical development for HIV seek to improve on the potency and/or safety of these same drug classes and antiviral resistance; however, over time the emergence and dominance of drug-resistant viruses to these drug classes increases.

Biotron is developing a new class of drug that attacks virus in cellular reservoirs that are poorly penetrated by ART. This approach aims to utilise the potency of current ART regimens that inhibit viral replication primarily in T cells and combine it with a novel inhibitor that reduces viral replication in cells of the monocyte-macrophage lineage. The aim is to reduce HIV-1 replication in a cellular reservoir that can act as a factory of virus production and potentially eliminate the vault of drug-resistant virus that infects these cells over the course of the HIV-1 infection.

Vpu Inhibitor

BIT225 represents a new, first-in-class drug for treatment of HIV. It is a novel, oral small molecule inhibitor of HIV-1 Vpu and specifically targets HIV in the monocyte-macrophage reservoir, which is currently not targeted with existing therapies. Vpu is a well conserved protein that forms a virus ion channel and is involved in the assembly and release of infectious viral particles.

Preclinical Data

BIT225 is a late-acting drug, interfering with production and release of productive, infectious virus, and preventing transmission of virus to uninfected CD4 T cells. It is active against multiple-drug resistant strains of HIV in vitro and synergistic or additive with current several current HIV drugs. Biotron has developed a transfer assay, which quantitates HIV transfer from the infected macrophage compartment to CD4 T cells; they have demonstrated that BIT225 can significantly reduce both the virus spread within the monocyte/macrophage compartment and the transfer of virus to CD4 T cells. Additionally, they have demonstrated that BIT225 can prevent transfer of HIV from endogenously infected monocyte cells isolated from HIV+ patients.

Clinical Data

In vitro studies have indicated that BIT225 targets HIV in monocyte-derived macrophage cells, which are one of the major reservoirs of virus in patients who have undergone antiretroviral treatment (ART). Depletion of these reservoirs is necessary to eliminate virus in patients, and current ART has been unsuccessful in clearing these long-lived pools of virus.

In December 2012, Biotron completed the clinical stage of a Phase 1b/2a trial (BIT225-004) of BIT225 in treatment-naive HIV-infected patients. This trial was a placebo-controlled, double-blinded, randomized study of the safety, pharmacokinetics (PK) and antiviral activity of BIT225 was undertaken in HIV-positive patients with high levels of virus and good CD4 T cell counts, not previously treated with ART. Patients received either BIT225 (300 mg; twice daily) or placebo for a period of 10 days. Preliminary results demonstrated that Biotron's BIT225 targets HIV replication in monocyte cells in treated patients, demonstrating the compound is capable of significantly reducing virus levels in these cells.

Advantages

BIT225 has the following advantages:

  • New mode of action drug
  • Novel Vpu inhibitor with the potential to eliminate one of the major reservoirs of HIV in the body
  • Active against multiple-drug resistant strains of HIV
  • Potential for use in HCV and HIV-1 co-infected patients.

Price History

52 Week High Change from 52 Week High % Change from 52 Week High 52 Week Low Change from 52 Week Low % Change from 52 Week Low
${{quote["Year's High"]}} ${{(quote["Historic Close"] - quote["Year's High"]) | setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's High"]) - 1) * 100) | setDecimalCheckForNa}}% ${{quote["Year's Low"] | setDecimalCheckForNa}} ${{(quote["Historic Close"] - quote["Year's Low"])| setDecimalCheckForNa}} {{(((quote["Historic Close"] / quote["Year's Low"]) - 1) * 100) | setDecimalCheckForNa}}%
Date Open High Low Close Volume

Upcoming Dividends

Organization Details RIC Dividend Amount Ex Dividend Date Dividend Payment Date Yield Franking % Earnings Current Price
{{UpcomingDividends[0]['Display Name']}} {{UpcomingDividends[0].RIC}} {{UpcomingDividends[0].Dividend}} {{UpcomingDividends[0]['Ex-Dividend Date']}} {{UpcomingDividends[0]['Dividend Date']}} {{UpcomingDividends[0]['Yield']}} {{UpcomingDividends[0]['GEN VAL2']}} {{UpcomingDividends[0].Earnings}} {{UpcomingDividends[0]['CF Last Price']}}
The next upcoming dividend date has not yet been announced - Please watch this place for updated dividend information

Historical Dividends

Dividend Yield Dividend Yield (5 Yr Avg) ISIN Stock Code (RIC) SEDOL Dividend Currency
{{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}} {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}} {{Dividends[0].ISIN}} {{Dividends[0].RIC}} {{Dividends[0].SEDOL}} {{Dividends[0].DividendCurrency != '' ? Dividends[0].DividendCurrency : '-'}}
Year CorpActID DPTD DivAnnDate DivExDate DivPayDate DTMD DivRate DRD DRPrice DTMD DTMD Frank%
{{item.DividendExDate == '01/01/1900' ? '-' : item.DividendExDate| date : 'dd/MM/yyyy'}} {{item.CorporateActionsID}} {{item.DividendPaymentTypeDescription}} {{item.DividendAnnoucementDate == '00/01/1900' ? '-' : item.DividendAnnoucementDate| date : 'dd/MM/yyyy'}} {{item.DividendExDate == '01/01/1900' ? '-' : item.DividendExDate| date : 'dd/MM/yyyy'}} {{item.DividendPayDate == '01/01/1900' ? '-' : item.DividendPayDate| date : 'dd/MM/yyyy'}} {{item.DividendTypeMarkerDescription}} {{item.DividendRate != '0' ? item.DividendRate : '-'}} {{item.DividendReinvestmentDeadline == '01/01/1900' ? '-' : item.DividendReinvestmentDeadline| date : 'dd/MM/yyyy'}} {{item.DividendReinvestmentPrice != '0' ? item.DividendReinvestmentPrice : '-'}} {{item.DividendTaxMarkerDescription != '' ? item.DividendTaxMarkerDescription : '-'}} {{item.DividendTaxRate != '0' ? item.DividendTaxRate :'-'}} {{item.FrankingPercent != '0' ? item.FrankingPercent : '-'}}

Share Statistics

  Revenue/Share Free Cash Flow Per Share Cash Flow Per Share Book Value Per Share Book Value(tangible) Per Share Cash Per Share
Most Recent Quarter - - - {{ratios['Per share data'].QBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QTANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].QCSHPS.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Per share data'].AREVPS.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].ACFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ATANBVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ACSHPS.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Per share data'].TTMREVPS.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMFCFSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMCFSHR.Value | setDecimalCheckForNa}} - - -
  Dividend Per Share EPS Normalized EPS Basic Exluding Extraordinary Items EPS Including Extraordinary Items EPS Excluding Extraordinary Items EBITD Per Share
Most Recent Fiscal Year {{ratios['Per share data'].ADIVSHR.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSNORM.Value | setDecimalCheckForNa}} {{ratios['Per share data'].ABEPSXCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSINCLXO.Value | setDecimalCheckForNa}} {{ratios['Per share data'].AEPSXCLXOR.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Per share data'].TTMDIVSHR.Value | setDecimalCheckForNa}} - {{ratios['Per share data'].TTMBEPSXCL.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSINCX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEPSXCLX.Value | setDecimalCheckForNa}} {{ratios['Per share data'].TTMEBITDPS.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Per share data'].ADIV5YAVG.Value | setDecimalCheckForNa}} - - - - -
Avg Vol(3 month) Avg Vol(10 day) Shares Outstanding Float % Held by Insiders % Held by Institutions Shares Short Shares Ratio Short % of Float Shares Short(prior month)
{{ratios['Price and Volume'].VOL3MAVG.Value | checkForNa}} {{ratios['Price and Volume'].VOL10DAVG.Value | checkForNa}} - - - - - - - -
Common Shareholders Shares Outstanding Shares Issued Float
{{generalInfo.CompanyGeneralInfo.CommonShareholders.Value | checkForNa}} {{sharesIssuedData.SharesOut | abbreviateNumber | checkForNa}} {{sharesIssuedData.SharesIssued | abbreviateNumber | checkForNa}} {{sharesIssuedData.Float | abbreviateNumber | checkForNa}}
Index Code Index name
{{item}} {{generalInfo.IndexMembership[item]}}
N/A N/A
Order Industry Type Code Mnemonic Reported
N/AN/AN/AN/AN/AN/A
{{detail.Order | checkForNa}} {{detail.Description | checkForNa}} {{industry | checkForNa}} {{detail.Code | checkForNa}} {{detail.Mnemonic | checkForNa}}

Valuation Ratios

  P/E excluding extraordinary items P/E Normalized P/E Basic excluding extraordinary items P/E excluding extraordinary items high P/E excluding extraordinary items low P/E including extraordinary items
Most Recent Fiscal Year {{ratios.Valuation.APEEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.APENORM.Value | setDecimalCheckForNa}} - - - -
TTM {{ratios.Valuation.PEEXCLXOR.Value | setDecimalCheckForNa}} - {{ratios.Valuation.PEBEXCLXOR.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPEHIGH.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPELOW.Value | setDecimalCheckForNa}} {{ratios.Valuation.PEINCLXOR.Value | setDecimalCheckForNa}}
  Price to Sales Price to Tangible Book Price to Free Cash Flow per Share Price to Cash Flow per Share Price to Book
Most Recent Fiscal Year {{ratios.Valuation.APR2REV.Value | setDecimalCheckForNa}} {{ratios.Valuation.APR2TANBK.Value | setDecimalCheckForNa}} {{ratios.Valuation.APRFCFPS.Value | setDecimalCheckForNa}} - {{ratios.Valuation.APRICE2BK.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios.Valuation.TTMPR2REV.Value | setDecimalCheckForNa}} - {{ratios.Valuation.TTMPRFCFPS.Value | setDecimalCheckForNa}} {{ratios.Valuation.TTMPRCFPS.Value | setDecimalCheckForNa}} -
Most Recent Quarter - {{ratios.Valuation.PR2TANBK.Value | setDecimalCheckForNa}} - - {{ratios.Valuation.PRICE2BK.Value | setDecimalCheckForNa}}
Dividend Yield - 5 Year Average {{ratios.Valuation.YLD5YAVG.Value | setDecimalCheckForNa}}
Dividend Yield - indicated annual dividend divided by closing price {{ratios.Valuation.YIELD.Value | setDecimalCheckForNa}}
Current Dividend Yield - Common Stock Primary Issue, LTM {{ratios.Valuation.DivYield_CurTTM.Value | setDecimalCheckForNa}}
Net Debt, LFI {{ratios.Valuation.NetDebt_I.Value | setDecimalCheckForNa}}
Net Debt, LFY {{ratios.Valuation.NetDebt_A.Value | setDecimalCheckForNa}}

Financial Strength Ratios

  Current ratio Quick ratio LT debt/equity Total debt/total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
  Payout ratio Current EV/Free Cash Flow Interest coverage Total debt/total equity
Most Recent Fiscal Year {{ratios['Financial strength'].APAYRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurA.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Financial strength'].TTMPAYRAT.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].EV2FCF_CurTTM.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} -
Income Statement Revenue EBITD Earnings before taxes Net Income available to common Earnings before taxes Normalized Earnings per Share, Normalized, Excluding Extraordinary Items, Avg. Diluted Shares Outstanding
Most Recent Fiscal Year {{ratios['Income Statement'].AREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].ANIAC.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].AEBTNORM.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios['Income Statement'].TTMREV.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBITD.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMEBT.Value | setDecimalCheckForNa}} {{ratios['Income Statement'].TTMNIAC.Value | setDecimalCheckForNa}} - {{ratios['Income Statement'].VDES_TTM.Value | setDecimalCheckForNa}}
  Gross Margin Net Profit Margin % Operating Margin Pre Tax Margin Free Operating Cash Flow/Revenue
1st Historical Fiscal Year {{ratios.Margins.AGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.ANPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.AOPMGNPCT.Value | setDecimalCheckForNa}} {{ratios.Margins.APTMGNPCT.Value | setDecimalCheckForNa}} -
Trailing 12 Months {{ratios.Margins.TTMGROSMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMNPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMOPMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.TTMPTMGN.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_TTM.Value | setDecimalCheckForNa}}
5 Year Average {{ratios.Margins.GROSMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.MARGIN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.OPMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.PTMGN5YR.Value | setDecimalCheckForNa}} {{ratios.Margins.Focf2Rev_AAvg5.Value | setDecimalCheckForNa}}
Risk Ratio Current Ratio Quick Ratio Interest Coverage LT Debt/Equity Total Debt/Total equity
Most Recent Quarter {{ratios['Financial strength'].QCURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QQUICKRATI.Value | setDecimalCheckForNa}} - {{ratios['Financial strength'].QLTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].QTOTD2EQ.Value | setDecimalCheckForNa}}
Most Recent Fiscal Year {{ratios['Financial strength'].ACURRATIO.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AQUICKRATI.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].AINTCOV.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ALTD2EQ.Value | setDecimalCheckForNa}} {{ratios['Financial strength'].ATOTD2EQ.Value | setDecimalCheckForNa}}
Trailing 12 Months - - {{ratios['Financial strength'].TTMINTCOV.Value | setDecimalCheckForNa}} - -

Management Effectiveness Ratios

Turnover Asset Inventory Receivables
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].ARECTURN.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMASTTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMINVTURN.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMRECTURN.Value | setDecimalCheckForNa}}
Return on Average Assets EBITD Equity Investment
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].AROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROIPCT.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMROAPCT.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].TTMROEPCT.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMROIPCT.Value | setDecimalCheckForNa}}
5 Year Average {{ratios['Mgmt Effectiveness'].AROA5YAVG.Value | setDecimalCheckForNa}} - {{ratios['Mgmt Effectiveness'].AROE5YAVG.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AROI5YRAVG.Value | setDecimalCheckForNa}}
Employees Net Income Revenue
Most Recent Fiscal Year {{ratios['Mgmt Effectiveness'].ANIPEREMP.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].AREVPEREMP.Value | setDecimalCheckForNa}}
Trailing 12 Months {{ratios['Mgmt Effectiveness'].TTMNIPEREM.Value | setDecimalCheckForNa}} {{ratios['Mgmt Effectiveness'].TTMREVPERE.Value | setDecimalCheckForNa}}

Growth Ratios

Growth Rates Revenue % EPS Dividend Revenue/Share Book Value Per Share Capital Spending Net Profit Margin
Most Recent Quarter 1 Year Ago {{ratios.Growth.REVCHNGYR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSCHNGYR.Value | setDecimalCheckForNa}} - - - - -
5 Years {{ratios.Growth.REVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} - {{ratios.Growth.REVPS5YGR.Value | setDecimalCheckForNa}} {{ratios.Growth.BVTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.CSPTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.NPMTRENDGR.Value | setDecimalCheckForNa}}
3 Years {{ratios.Growth.REVGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.EPSGRPCT.Value | setDecimalCheckForNa}} {{ratios.Growth.DIVGRPCT.Value | setDecimalCheckForNa}} - - - -
TTM over TTM {{ratios.Growth.EPSTRENDGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TTMEPSCHG.Value | setDecimalCheckForNa}} - - - - -
CAGR Free Operating Cash Flow Earnings Before Interest, Taxes, Depreciation & Amortization Tangible Book Value Total Debt
5 Year CAGR {{ratios.Growth.FOCF_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.Ebitda_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.TanBV_AYr5CAGR.Value | setDecimalCheckForNa}} {{ratios.Growth.STLD_AYr5CAGR.Value | setDecimalCheckForNa}}
5 Year Interim CAGR - {{ratios.Growth.Ebitda_TTMY5CAGR.Value | setDecimalCheckForNa}} - -

Forecast Ratios

Projected Sales ProjSalesH ProjSalesL ProjSalesNumOfEst ProjSalesPS
{{forecasts.ProjSales | setDecimalCheckForNa}} {{forecasts.ProjSalesH | setDecimalCheckForNa}} {{forecasts.ProjSalesL | setDecimalCheckForNa}} {{forecasts.ProjSalesNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjSalesPS | setDecimalCheckForNa}}
ProjSalesQ ProjSalesQH ProjSalesQL ProjSalesQNumOfEst Price2ProjSales
{{forecasts.ProjSalesQ | setDecimalCheckForNa}} {{forecasts.ProjSalesQH | setDecimalCheckForNa}} {{forecasts.ProjSalesQL | setDecimalCheckForNa}} {{forecasts.ProjSalesQNumOfEst | setDecimalCheckForNa}} {{forecasts.Price2ProjSales | setDecimalCheckForNa}}
ProjEPS ProjEPSHigh ProjEPSLow ProjEPSNumOfEst ProjEPSQ
{{forecasts.ProjEPS | setDecimalCheckForNa}} {{forecasts.ProjEPSH | setDecimalCheckForNa}} {{forecasts.ProjEPSL | setDecimalCheckForNa}} {{forecasts.ProjEPSNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjEPSQ | setDecimalCheckForNa}}
ProjEPSQH ProjEPSQL ProjEPSQNumOfEst ProjPE ProjLTGrowthRate
{{forecasts.ProjEPSQH | setDecimalCheckForNa}} {{forecasts.ProjEPSQL | setDecimalCheckForNa}} {{forecasts.ProjEPSQNumOfEst | setDecimalCheckForNa}} {{forecasts.ProjPE | setDecimalCheckForNa}} {{forecasts.ProjLTGrowthRate | setDecimalCheckForNa}}
TargetPrice EPSActual EPSPrev EPSSurprise EPSSurprisePrc
{{forecasts.TargetPrice | setDecimalCheckForNa}} {{forecasts.EPSActual | setDecimalCheckForNa}} {{forecasts.EPSPrev | setDecimalCheckForNa}} {{forecasts.EPSSurprise | setDecimalCheckForNa}} {{forecasts.EPSSurprisePrc | setDecimalCheckForNa}}
EPSActualQ EPSPrevQ EPSSurpriseQ EPSSurpriseQPrc
{{forecasts.EPSActualQ | setDecimalCheckForNa}} {{forecasts.EPSPrevQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQ | setDecimalCheckForNa}} {{forecasts.EPSSurpriseQPrc | setDecimalCheckForNa}}
ProjProfit ProjProfitH ProjProfitL ProjProfitNumOfEst
{{forecasts.ProjProfit | setDecimalCheckForNa}} {{forecasts.ProjProfitH | setDecimalCheckForNa}} {{forecasts.ProjProfitL | setDecimalCheckForNa}} {{forecasts.ProjProfitNumOfEst | setDecimalCheckForNa}}
ProjDPS ProjDPSH ProjDPSL ProjDPSNumOfEst
{{forecasts.ProjDPS | setDecimalCheckForNa}} {{forecasts.ProjDPSH | setDecimalCheckForNa}} {{forecasts.ProjDPSL | setDecimalCheckForNa}} {{forecasts.ProjDPSNumOfEst | setDecimalCheckForNa}}

Financial Reports

Financial Summary

Last Updated: {{generalInfo.TextInfo['Financial Summary'].LastUpdated}}

{{generalInfo.TextInfo['Financial Summary'].Value && generalInfo.TextInfo['Financial Summary'].Value != ''? generalInfo.TextInfo['Financial Summary'].Value: 'No Financial Summary Found.'}}


Accounting Notes
Fiscal Year Ends Most Recent Quarter Transfer agent Auditor Shariah Compliant

{{generalInfo.CompanyGeneralInfo.TotalSharesOut.Data | date:'dd/MM/yyyy' }}

-

- - {{generalInfo.Auditor && generalInfo.Auditor != ''? generalInfo.Auditor : '-'}}
Fiscal Period
Period End Date:
Period Length
Ratios Value
Analyst Footnotes

Last Updated: {{generalInfo.TextInfo['Analyst Footnotes'].LastUpdated}}

{{generalInfo.TextInfo['Analyst Footnotes'].Value && generalInfo.TextInfo['Analyst Footnotes'].Value != '' ? generalInfo.TextInfo['Analyst Footnotes'].Value : 'No Analyst Footnotes Found.'}}



Directors, Officers & Company Executives

Start Date End Date
{{personobject.PersonInformation.Name.Info| getDirectorFullNameIncludingPrefix}}
{{persontitlesobject.Value}}, {{persontitles.Start.Day}}-{{persontitles.Start.Month}}-{{persontitles.Start.Year}} {{persontitles.End.Day}}-{{persontitles.End.Month}}-{{persontitles.End.Year}}
No Directors, Officers & Company Executives Information Found.

Recommendation Statistics

No Recommendation Statistics

Recommendation Statistics
Recommendation Number Of Analysts
Sell Reduce Hold Buy Strong Buy {{stats.NumberOfAnalysts}}
I/B/E/S Mean
{{verdict[meanmarker]}} {{analystvotes}} Analysts Mean recommendation from all analysts covering the company on a standardized 5-point scale.
  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Past Broker Recommendations

No Past Recommendations

Past Broker Recommendations
  Sell Underperform Hold Buy Strong Buy Total
{{snapshots.Age === 1 ? "1 Week Ago" : (snapshots.Age === 2 ? "30 Days Ago" : (snapshots.Age === 3 ? "60 Days Ago" : (snapshots.Age === 4 ? "90 Days Ago" : "")))}} {{snapshots.Statistics[0].NumberOfAnalysts}} {{snapshots.Statistics[1].NumberOfAnalysts}} {{snapshots.Statistics[2].NumberOfAnalysts}} {{snapshots.Statistics[3].NumberOfAnalysts}} {{snapshots.Statistics[4].NumberOfAnalysts}} {{snapshots.NumberOfRecommendations}}

Target Price

No Target Price

Target Price
Mean {{priceTarget.Mean}}
High {{priceTarget.High}}
Low {{priceTarget.Low}}
Median {{priceTarget.Median}}
Standard Devitation {{priceTarget.StandardDeviation}}
Number Of Estimates {{priceTarget.NumberOfEstimates}}

Videos

No Videos Found

Click here to view video
Video Preview
Video Preview

{{video.summary}}




Contact Info

Biotron Limited

Suite 1.9,
56 Delhi Road
North Ryde, NSW
AU Australia, 2113

Phone: +61 2 9805 0488
Fax: +61 2 9805 0688
Email: enquiries@biotron.com.au
Website: http://www.biotron.com.au

Click here to view the interactive map
Biotron Limited Google Map
Biotron Limited Google Map

Share Registry

Computershare Investor Services Pty Limited - Click here to view share registry profile

Phone: +61 3 9415 5000
Fax: +61 3 9473 2500
Email: investor.relations@computershare.com.au
Website: http://www.computershare.com/

452 Johnston Street
Abbotsford, VIC
AU Australia, 3067


Important Information

The General Overview, Services, Products and Projects information for this profile was last edited on 10 Jun 2015.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.

Home

Search

Login

Report a bug